Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies
Astellas Pharma has entered into a collaboration with Kelonia Therapeutics to create in vivo CAR T-therapies through genetic cargo delivery. This technology enables the modification of immune cells, targeting cancer cells and improving the ability to destroy tumors. The collaboration will develop up to two in vivo CAR T-therapy programs, with undisclosed targets. Kelonia will…